Reprint
Human Papillomavirus and Cancers
Edited by
July 2024
404 pages
- ISBN978-3-7258-1714-6 (Hardback)
- ISBN978-3-7258-1713-9 (PDF)
This is a Reprint of the Special Issue Human Papillomavirus and Cancers that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
In the Special Issue, several experts from all over the world report and discuss the most recent advances from basic science to the clinical management of HPV-related malignancies, especially highlighting the oncogenic role of epigenetic factors, viral proteins and the immune response in HPV-driven cancers, as well as new anti-cancer opportunities, including HPV-based therapeutic vaccines.
Format
- Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
head and neck cancer; squamous cell carcinoma; human papillomavirus (HPV); oral cavity tumors; oropharyngeal cancer; p16Ink4a biomarker; p16-immunostaining; prognosis; overall survival; human papillomavirus; head and neck cancer; double-stranded DNA breaks; DNA repair; cell line; cyclin B1; Aurora Kinase A; human papillomavirus; MHC-II; major histocompatibility complex; antigen presentation; head and neck carcinoma; co-stimulatory molecules; survival signals; T-cell; human papillomavirus; head and neck cancer; cancer metabolism; glycolysis; cellular respiration; TCGA; cervical intraepithelial neoplasia; high-risk human papillomavirus; multistate Markov model; retrospective cohort study; survival analysis; hypoxia; human papillomavirus; oropharyngeal squamous cell carcinoma; centrosome amplification; miRNA; human papillomavirus; innate immunity; cancer; intracellular antiviral response; immune evasion; organoid; uterine cervix; squamocolumnar junction; human papillomavirus; Matrigel; human papillomavirus; head and neck squamous cell carcinoma; cell cycle; D-type cyclins; CCND1; CCND2; CCND3; patient survival; paired tumor-normal samples; 11q13 amplification; human papilloma virus; squamous cell carcinoma of the head and neck; translational research; oncogenes; tumor suppressor genes; human papillomavirus; cervical screening; diagnostic testing; self-collection; oropharyngeal squamous cell carcinoma; human papillomavirus; recurrence; surface brushing; EGFR; human papillomaviruses (HPVs)-related cancers; tumor microenvironment (TME); 3D organotypic models; cervical cancers; anogenital cancers; oropharynx cancers; Ureaplasma spp.; sexually transmitted infections; human papillomavirus; oropharyngeal cancer; brush test; HPV; squamous cell carcinoma; non-coding RNAs; circular RNAs; PIWI-interacting RNAs; long non-coding RNAs; therapeutic antibodies; single-chain antibody fragments; HPV-associated cancer; clinical stage antibodies; Human Papillomavirus 16 E6 and E7 oncoproteins; papillomavirus; HPV; CRISPR; gene therapy; viral vector; adenovirus; anal cancer; HPV; cancer-associated circulating cells; liquid biopsies; human papillomavirus; oropharyngeal cancer; E7 oncoprotein; brush test; p16 IHC; non-AIDS defining cancers (NADC); AIDS defining cancers (ADC); human papillomavirus type 16 (HPV16); opportunistic HPV infections; oropharyngeal cancer; cervical cancer; highly active anti-retroviral therapy (HAART); protease inhibitors; organotypic raft cultures; HPV persistence; Juvenile-onset recurrent respiratory papillomatosis; HPV 6; HPV 11; RNA; chromogenic in situ hybridization; plant molecules; HPV-related tumors; DNA vaccination; multimodal treatments; immunomodulation; immunotherapy; combined DNA vaccine/plant molecule therapy; chimeric vaccine; n/a